Graduate Program in Pharmaceutical Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil.
Center for Pharmacometrics & Systems Pharmacology, College of Pharmacy, University of Florida at Lake Nona, Orlando, FL, USA.
J Clin Pharm Ther. 2021 Jun;46(3):610-621. doi: 10.1111/jcpt.13369. Epub 2021 Feb 3.
Meropenem, a carbapenem antibiotic, is widely prescribed for the treatment of life-threatening infections. The main parameter associated with its therapeutic success is the percentage of time that the levels remain above the minimum inhibitory concentration. Inadequate levels of meropenem can lead to therapeutic failure and increase the possibility of microbial resistance. The employment of strategies involving dose regimens and drug pharmacodynamics has become increasingly important to optimize therapies. In the present study, we conducted a review with the purpose of assembling information about the clinical use of meropenem and therapeutic drug monitoring.
A literature review emphasizing the application of therapeutic drug monitoring (TDM) of meropenem in clinical practice has been done. To identify articles related to the topic, we performed a standardized search from January 21, 2020 to December 21, 2020, using specific descriptors in PubMed, Lilacs and Embase.
In total, 35 studies were included in the review. The daily dose of meropenem commonly ranged from 3 to 6 g/day. Critically ill patients and those with impaired renal function appear to be the most suitable patients for the application of meropenem TDM, in order to guide therapy. We observed that most of the studies recommend TDM and that, in nine locations, the TDM of meropenem and of other beta-lactams is a routine practice. TDM data can help to maximize the clinical outcomes of the treatment with meropenem. It can also improve the patient care by providing suitable levels of meropenem, guiding the most appropriate dose regimens, which is the main parameter associated with therapeutic success.
The findings from this review suggest that the therapeutic monitoring of meropenem can be beneficial, since it adjusts the treatment and aids clinical outcomes. It does so by indicating the appropriate dosage and preventing failure, toxicity and possible antimicrobial resistance. The multidisciplinary effort, basic knowledge and communication among the medical team are also essential.
美罗培南是一种碳青霉烯类抗生素,被广泛用于治疗危及生命的感染。与治疗成功相关的主要参数是药物浓度高于最低抑菌浓度的时间百分比。美罗培南水平不足会导致治疗失败,并增加微生物耐药的可能性。涉及剂量方案和药物药代动力学的策略的应用对于优化治疗变得越来越重要。在本研究中,我们进行了一项综述,旨在收集有关美罗培南临床应用和治疗药物监测的信息。
我们对强调在临床实践中应用美罗培南治疗药物监测(TDM)的文献进行了综述。为了确定与该主题相关的文章,我们在 2020 年 1 月 21 日至 2020 年 12 月 21 日期间,在 PubMed、Lilacs 和 Embase 中使用特定的描述符进行了标准化搜索。
共纳入 35 项研究。美罗培南的常用日剂量通常为 3 至 6g/天。危重症患者和肾功能受损患者似乎最适合进行美罗培南 TDM,以指导治疗。我们观察到大多数研究都推荐 TDM,在九个地点,美罗培南和其他β-内酰胺类药物的 TDM 是常规做法。TDM 数据有助于最大限度地提高美罗培南治疗的临床效果。它还可以通过提供适当的美罗培南水平、指导最合适的剂量方案来改善患者的护理,这是与治疗成功相关的主要参数。
本综述的结果表明,美罗培南的治疗监测可能是有益的,因为它可以调整治疗并有助于临床结果。它通过指示适当的剂量、预防失败、毒性和可能的抗菌耐药性来实现这一目标。医疗团队的多学科努力、基础知识和沟通也是必不可少的。